Toggle light / dark theme

Engineered albumin helps a therapeutic protein last longer and cross mucosal barriers

Protein-based medicines have transformed the treatment of many diseases, but they often come with a limitation: they must be injected, sometimes repeatedly, because they are rapidly cleared from the bloodstream. For patients who depend on long-term or lifelong treatment, frequent injections place a considerable burden on everyday life.

Now, researchers from the University of Oslo and Oslo University Hospital, together with international collaborators, have developed an approach to make a therapeutic protein last longer in the body while also opening the possibility of delivering it across mucosal surfaces without the use of needles. The work is published in Nature Communications.

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.